Atara Biotherapeutics, Inc. (41) | License Agreements (6)
Recent Contracts
-
Fourth Amended and Restated Exclusive License Agreement between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated December 17, 2021
(Filed With SEC on February 28, 2022)
-
Deed of Amendment Number 1 to Third Amended and Restated License Agreement dated April 21, 2021
(Filed With SEC on August 9, 2021)
-
Research, Development and License Agreement, by and between Atara Biotherapeutics, Inc. and Bayer AG, dated December 4, 2020
(Filed With SEC on March 1, 2021)
-
Third Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated August...
(Filed With SEC on November 9, 2020)
-
Second Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated August...
(Filed With SEC on November 7, 2019)
-
Amendment No. 1 to the Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and Memorial Sloan Kettering Cancer Center, dated as of August 30, 2018
(Filed With SEC on February 26, 2019)